首页> 外文期刊>Leukemia Research Reports >Aspirin and risk of multiple myeloma in adults: A systematic review and meta-analysis
【24h】

Aspirin and risk of multiple myeloma in adults: A systematic review and meta-analysis

机译:成人阿司匹林和多发性骨髓瘤的风险:系统评价和荟萃分析

获取原文
       

摘要

Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58?1.39; P=0.638). Odds ratios from the two case-control studies were similar. The findings demonstrated that there was no significant association between aspirin use and the risk of multiple myeloma. Highlights ? This is a systematic review of aspirin use on the incidence risk of multiple myeloma. ? There is no evidence that aspirin modifies the risk of multiple myeloma. ? More studies are needed to assess the impact of aspirin on the risk of multiple myeloma.
机译:多发性骨髓瘤是一种相对罕见的浆细胞恶性肿瘤。临床前和临床研究表明,阿司匹林可能会改变多发性骨髓瘤的风险。我们对研究进行了系统的综述和荟萃分析,以检查常规阿司匹林使用与多发性骨髓瘤风险之间的关联。评价了五项观察性研究,包括332,660名成年人。汇总估计的危险比为0.90(95%置信区间= 0.58-1.39; P = 0.638)。两项病例对照研究的赔率相似。研究结果表明,使用阿司匹林与多发性骨髓瘤的风险之间没有显着关联。强调 ?这是阿司匹林对多发性骨髓瘤发生风险的系统评价。 ?没有证据表明阿司匹林可改善多发性骨髓瘤的风险。 ?需要更多的研究来评估阿司匹林对多发性骨髓瘤风险的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号